Navigation Links
Also in the March 24 JNCI
Date:3/24/2009

>

Analysis Identifies Possible Prognostic Markers in Melanoma and Need for Better Methodology

A systematic literature review and meta-analysis of published studies found several promising markers associated with clinical outcome in early-stage melanoma patients. However, the review also revealed that numerous published reports did not meet the minimum guidelines established in 2005 for biomarker studies.

Some patients with early stage melanoma can be treated with surgery alone. However, biomarkers that distinguish these patients from patients who will have recurrent disease have not emerged, despite numerous reports of putative markers in the literature.

To better understand why this disconnect exists, Bonnie Gould Rothberg, M.D., of the Yale University School of Medicine in New Haven, Conn., and colleagues performed a systematic literature review and meta-analysis of studies that reported on putative protein biomarkers associated with clinical outcome in patients with early melanoma. The investigators restricted their analysis to studies that used immunohistochemistry-based biomarker detection.

The team initially identified 102 cohort studies in the literature, but only 37 met all of their inclusion criteria. Twenty-seven studies were excluded by the investigators because they lacked adequate methodological information, despite having been published after 2005, when the medical research community established minimum guidelines for publication of biomarker studies, called REMARK.

The thirty-seven studies that met the inclusion criteria for the meta-analysis evaluated 62 protein markers. Several promising markers emerged, including MCAM/MUC18, matrix metalloproteinase-2, Ki-67, PCNA, and p16/INK4A.

"This systematic reviewsupports involvement of cyclin-dependent kinase inhibitors, effectors of DNA replication and cell proliferation, growth-promoting transcription factors, and multiple regul
'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. JCI table of contents: March 23, 2009
2. Capitol Hill Briefing Scheduled for March 24 to Promote Colorectal Cancer Screening and Care
3. Herley Chairman Addresses Shareholders at Annual Meeting of Shareholders March 17, 2009
4. Hospice of Michigan Documentary to Air on Detroit Public Television Monday, March 23 and Sunday, March 29
5. NSC Hosts National Poison Prevention Week News Conference, Tuesday, March 17
6. Poison Prevention Week March 15 - 22
7. Optometry Career Conferences Set for Five N.C. Campuses in March
8. China Sky One Medical to Attend Two Conferences in March
9. Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
10. Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City
11. China Pharma Holdings, Inc. to Host Fourth Quarter 2008 Earnings Conference Call at 8:30 a.m. EDT Wednesday March 18, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...
(Date:5/21/2013)... May 21, 2013 Vyopta Incorporated, ... automation applications for video collaboration, today announced the ... index evaluates key performance metrics related to quality, ... immediate, aggregated indicator of the performance of their ... Vyopta vAnalytics™ application, the vRating™ delivers high level ...
(Date:5/21/2013)... TheBeautyPlace.com helps brides to breathe a ... Big Day Kit including all the essentials a glowing ... on their Wedding Day. , TheBeautyPlace.com features Wedding Day ... their Wedding Day. Flowers blooming and warmer weather indicates ... season. From Memorial Day to October, brides to be ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
Breaking Medicine News(10 mins):Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 2Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 3Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3
... May 16 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... that the Company,will present at the following conferences:, ... cities in China. David Gao, ... scheduled to present on May 19, 2008, ...
... University of Texas M. D. Anderson Cancer Center have ... shutting down their energy source and hastening cell starvation. ... fellow from the Children,s Cancer Hospital at M. D. ... with mTOR inhibitor, rapamycin, induced more than 90 percent ...
... Available, RADNOR, Pa., May 16 This ... Older Pennsylvanians Month, Feeling Blue,Suicide Prevention Council (SPC) ... a public service announcement. The public service,announcement developed ... awareness,to the public health problem of depression and ...
... Conn., May 16 Tao Formulations announces ... Relief Formula, at the Internal,Medicine 2008 conference ... culmination of years of research to develop ... menopausal symptoms., Company founder and CEO, ...
... 2 Diabetes and High LDL- ... Cholesterol ... ACE/AACE Road Maps, PARSIPPANY, N.J., May 16 Daiichi Sankyo, Inc. (DSI),announced ... combination with metformin- or,sulfonylurea- based therapy, significantly lowers blood glucose (as,measured by A1C) ...
... number of women undergoing mastectomy (total breast removal) for ... years at Mayo Clinic in Rochester. The increase follows ... Researchers say the reasons for this increase are unclear. ... who underwent diagnostic magnetic resonance imaging (MRI) prior to ...
Cached Medicine News:Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... 5.0 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: